Navigation Links
SemBioSys announces second quarter 2008 financial and operational results
Date:8/5/2008

ss) 11,958 153,036 (66,707) 170,985

------------ ------------ ------------ ------------

------------ ------------ ------------ ------------

65,195 361,945 95,724 534,154

------------ ------------ ------------ ------------

Net loss and

comprehensive loss

for the period (6,414,856) (3,225,371) (11,431,911) (6,453,782)

Deficit - Beginning

of period (61,176,218) (43,968,897) (56,159,163) (40,740,486)

------------ ------------ ------------ ------------

------------ ------------ ------------ ------------

Deficit - End of

period (67,591,074) (47,194,268) (67,591,074) (47,194,268)

------------ ------------ ------------ ------------

------------ ------------ ------------ ------------

Loss per share -

basic and diluted (0.25) (0.15) (0.44) (0.31)

------------ ------------ ------------ ------------

------------ ------------ ------------ ------------

Weighted average

shares outstanding 25,937,476 22,089,356 25,936,634 20,511,557

------------ ------------ ------------ ------------

------------ ------------ ------------ ------------

SemBioSys Genetics Inc.

Consolidated Statements of Cash Flows

(Unaudited)

-------------------------------------------------------------------------

(expressed in Canadian dollars)

Three month period ended Six month period ended

June 30, June 30, June 30, June 30,

2008 2007
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. SemBioSys submits IND for safflower-produced insulin to U.S. FDA
2. SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
3. SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference
4. SemBioSys provides update on shrimp feed additive, Immunosphere(TM)
5. SemBioSys announces first quarter 2008 financial and operational results
6. SemBioSys receives milestone payments from AVAC Ltd.
7. SemBioSys initiates toxicology study for safflower-produced insulin
8. SemBioSys announces 2007 financial and operational results
9. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
10. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
11. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email: